Active	Status	Sponsor type	Region	Phase	Filter
12 Active 1 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shi, Yehui
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer	Recruiting	2/3	254	RoW	SPH4336 Tablets, SPH4336 Tablets Placebo	Shanghai Pharmaceuticals Holding Co., Ltd	Locally Advanced or Metastatic Breast Cancer	03/25	08/25
TQB3616-II-04, NCT06702618: Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer	Not yet recruiting	2	33	RoW	TQB3616 capsule+Fulvestrant Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Breast Cancer	05/26	12/26
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.	Recruiting	2	52	RoW	SPH4336 Tablets	Shanghai Pharmaceuticals Holding Co., Ltd	Breast Cancer Brain Metastases	12/25	12/25
NCT04719065: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor	Active, not recruiting	1	90	RoW	Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Solid Tumor	04/22	04/24
KY-0118-ZJKY, NCT06175780: Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors	Recruiting	1	189	RoW	KY-0118	Novatim Immune Therapeutics (Zhejiang) Co., Ltd.	Neoplasms, Neoplasms by Histologic Type	12/25	12/25
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors	Active, not recruiting	1	208	US, RoW	BB-1701	Bliss Biopharmaceutical (Hangzhou) Co., Ltd	Locally Advanced/Metastatic HER2 Positive Solid Tumors	08/24	12/24
NCT04928612: A Study of CBP-1018 in Patients With Advanced Solid Tumors	Recruiting	1	170	RoW	CBP-1018	Coherent Biopharma (Suzhou) Co., Ltd.	Solid Tumor	10/24	12/24
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors	Recruiting	1	150	RoW	SPH5030 tablets	Shanghai Pharmaceuticals Holding Co., Ltd	HER2-positive Advanced Solid Tumors	12/24	12/24
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection	Recruiting	1	216	RoW	BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection	Bio-Thera Solutions	Advanced Solid Tumors	12/24	12/25
TQB2102-Ib-01, NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer	Recruiting	1	150	RoW	TQB2102 for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Breast Cancer	12/25	12/26
NCT05781633: The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.	Recruiting	N/A	43	RoW	eutidrone etoposide bevacizumab	Tianjin Medical University Cancer Institute and Hospital	Mammary Neoplasms, Human	07/23	07/25
NCT06438055: Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results	Not yet recruiting	N/A	40	NA	Chemotherapy and targeted-therapy guided by organoid drug sensitivity test	Tianjin Medical University Cancer Institute and Hospital, Kingbio Medical (Beijing) Co., Ltd.	Refractory Breast Cancer	06/25	06/26